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Abstract — Aims: To identify prognostic factors to outpatient alcohol treatment on admission as well as during the treatment
period. Methods: A cohort study of n = 209 alcoholic patients (DSM-IV) during 6 months of outpatient treatment. Eight medical
doctors from two hospitals were involved. Co-responsible participation in treatment was a necessary condition. At admission, we
documented socio demographic factors, use of other drugs and severity of alcohol consumption. During the 6 months, we observed
medication for prevention of alcohol relapse [disulfiram (DIS), acamprosate], number of sessions with the doctor, number of phases
of the consultation and medication for depression. Primary outcome variables were time to first heavy relapse and abstinence of
heavy alcohol consumption. These were measured with Timeline Followback. Five or more alcohol units of 10 g in one relapse day
were considered heavy relapse. Results: The patients were 84% males, with 41 years median age; the median alcohol consumption
was 192 g per day with a median duration of 13 years of heavy consumption. The median education was 6 years with 61% of the
patients from lower socio-economic levels. The Kaplan–Meier heavy relapse rate at 6 months was 23%. On admission to treatment,
female gender, lower socio-economic levels, cocaine use, >20 years of consumption, gamma glutamyl transferase values above
normal and five or more alcohol-related problems on the Alcohol-Related Problem Questionnaire predicted worse outcomes. Having
a full-time job and shorter abstinence time before treatment (until 7 days) predicted better outcomes. During the 6 months, we found
that DIS for <120 days was a prognostic factor of worse outcomes. DIS for at least 120 days, >50% of adherence to consultations
and more than two phases on each consultation predicted better outcomes. The combined sensitivity and specificity for DIS for at
least 120 days, >50% of adherence to consultations and more than two phases on consultation regarding abstinence from heavy
relapse were respectively 100 and 71%. Conclusions: During 6 months of outpatient treatment, longer adherence to DIS and consul-
tations as well as more phases in a consultation involving necessarily a co-responsible predict a good outcome independently of the
patient features at admission.
INTRODUCTION
The World Health Organization ranked alcohol as the third
most important risk factor for the increase in the number of
disability-adjusted life years in Portugal, as well as in
Europe, preceded by tobacco smoking (second risk factor)
and hypertension (first risk factor) (WHO, 2005).
Portugal is a country with a traditional culture of wine pro-
duction and consumption.
Nearly, 7% of the population aged 15 years or more is
alcohol dependent (Gameiro, 1998; Mello et al., 2001;
Direcção Geral de Saúde, 2004). The mean alcohol consump-
tion of male drinkers in the general population is 47.3 g per
day and 17.1 g for female drinkers (Marques-Vidal and Dias,
2005), alcohol dependence in Portugal being more prevalent
in males than in females (ratio 8 to 1: Gameiro, 1998).
About 6 of 10 patients with alcohol dependence will relapse
in the 6 months following detoxification, as estimated by the
median of 61% relapse rate obtained in several studies (Elis
and McClure, 1992; Barrias et al., 1997; Besson et al., 1998;
Chick et al., 2000; Curran et al., 2000; Rubio et al., 2001; Neto
et al., 2007; Nielsen et al., 2007; Terra et al., 2008). This high
rate of relapse in a relatively short period is a reason for search-
ing for the factors that better predict treatment outcomes.
Several treatment baseline factors were studied suggesting
that professional and marital stability are associated with
good prognosis (Waisberg, 1990; Glenn and Parsons, 1991;
McKay and Weiss, 2001; Walton et al., 2003; Bottlender and
Soyka, 2005a; Moos and Moos, 2006; Walter et al., 2006;
Terra et al., 2008). Besides this, low education level and
lower socio-economic level suggest worse prognosis (McKay
and Weiss, 2001; Moos and Moos, 2006; Ilgen et al., 2007).
More age at treatment admission is generally a good prog-
nostic factor (McKay and Weiss, 2001; Gordon et al., 2006;
Moos and Moos, 2006; Chong and Lopez, 2008). The results
for gender are contradictory revealing female gender asso-
ciated with good prognostics (Rounsaville et al., 1987;
McKay and Weiss, 2001; Gordon et al., 2006; Moos and
Moos, 2006) as well as bad prognostics (Ellis and McClure,
1992; Bottlender and Soyka, 2005b).
According to Staines et al. (2003), >60% of alcohol-
dependent patients use other drugs such as cocaine, heroin
and cannabis. The literature suggests contradictory results
such as drug use at treatment baseline associated with worse
treatment outcomes (Rounsaville et al., 1987) or drug use
associated with better outcomes (Chong and Lopez, 2008).
In respect of alcohol severity at treatment baseline, several
authors suggest that worse severity is associated with worse
prognostics (McLellan et al., 1994; McKay and Weiss, 2001;
Staines et al., 2003; Bottlender and Soyka, 2005a; Moos and
Moos, 2006; Ilgen et al., 2007), but it was mentioned as well
that severity could be a prognostic factor of good outcomes,
certainly for motivational reasons (Waisberg, 1990; McKay
and Weiss, 2001; Staines et al., 2003).
During the treatment period, the efficacy of pharmaco-
logical drugs for relapse prevention such as disulfiram (DIS),
acamprosate (ACA) and naltrexone is well documented
(Chick et al., 1992; Barrias et al., 1997; Besson et al., 1998;
Tempesta et al., 2000; Streeton and Whelan, 2001; Guardia
et al., 2002; Niederhofer and Staffen, 2003; Kiritzé-Topor
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et al., 2004; Mann et al., 2004; Kiefer et al., 2005; Verheul
et al., 2005; Feeney et al., 2006; Laaksonen et al., 2007;
Neto et al., 2007). Treatment adherence is important (McKay
and Weiss, 2001; Kiritzé-Topor et al., 2004) including the
adherence to medical consultations during treatment
(McCrady and Epstein, 2004; Mann et al., 2005; Terra et al.,
2008). Also, the style of the consultation matters: involving
the patient co-responsible in the consultation at a number of
separate points (Neto et al., 2008).
Alcoholic anonymous (AA) participation predicted good out-
comes in studies (Ellis and McClure, 1992; McKay and Weiss,
2001;Room et al., 2005; Ilgen et al., 2007; Terra et al., 2008).
Depression was as a bad prognostic factor in some studies
(Glenn and Parsons, 1991; Ellis and McClure, 1992;
Greenfield et al., 1998; Curran et al., 2000; Staines et al.,
2003; Bottlender and Soyka, 2005a,b). But in other studies,
depression at baseline also proved to be associated with
favourable outcomes (Terra et al., 2008).
With this background, we set as the general study object-
ive the role of each of the aforementioned factors in the
prognosis of outpatient treatment in a sample of alcoholic
patients treated in the public sector in Lisbon, Portugal.
METHODS
Design
The study was conducted in an observational clinical cohort
of alcohol-dependent patients followed during 6 months of
outpatient treatment (follow-up period). The sample com-
prised 209 patients selected according to Diagnostic and
Statistical Manual of Mental Disorders DSM-IV (APA,
1994; APA, 2002) in two hospital centers: Unidade de
Alcoologia de Lisboa (n = 194) and Hospital Nossa Senhora
do Rosário (n = 15), being the data collection authorized by
institution ethical approval (Neto et al., 2008).
The responsibility for a patient’s treatment was taken by
one of eight medical doctors, of whom six were male, and
whose professional experience was between 14 and 31 years
(average experience of 24 years). The tradition in these hos-
pitals is that medical doctors see the patient from the outset
and offer regular medical consultations to prevent relapse,
sometimes also involving a psychologist or a social worker.
A necessary condition for entry to this study was the avail-
ability of a co-responsible person (usually a family member)
to provide information to the researchers and assist with the
maintenance of abstinence.
The patients were sequentially and randomly assigned to
either ‘sequential combined treatment’ or ‘treatment as
usual’. The sequential combined treatment uses up to four
phases in one of the consultations: the first phase with the
patient and the co-responsible, the second with the patient
alone, the third phase with the co-responsible alone and the
fourth phase with the patient and the co-responsible again.
Treatment as usual uses up to two phases in one consult-
ation: the first phase with the patient alone and sometimes a
second phase with patient and the co-responsible. The effect-
iveness of the sequential combined treatment in comparison
with the usual treatment was shown previously by Neto
et al. (2008). With the three or four phases, the length of the
consultations was no >30 min. Each patient was invited to
make seven clinic visits during the six treatment months.
Patient selection
The co-responsible persons were husband/wife in 61% of
cases; the others were close friends, colleagues, social workers
or justice officers. All patients and their co-responsibles signed
an informed consent to participate in the study. The
co-responsible assumed the role of key informant as well as
collaborator in the treatment. When requested by the doctor and
accepted by the patient, the co-responsible had the responsibil-
ity of observing the ingestion of DIS by the patients.
The patients included had to be abstinent for at least 24 h
without signs of withdrawal syndrome. Patients were
excluded from the study if they had severe psychiatric or
physical co-morbidity, active co-morbidity associated with
substances other than tobacco, previous allergic reactions to
DIS and de-compensated hepatic disease, or were illiterate.
Prognostic factors at baseline
At admission to treatment, we recorded the basic demograph-
ics, including socio-economic level (Graffard, 1956), status
of co-responsible, stable sexual and emotional relationship,
family and social situation; past use of illicit drugs, benzo-
diazepines and past or actual tobacco smoking.
To measure severity of alcohol consumption, we recorded
years of heavy consumption—defined as 50 g per day or
more—alcohol quantity in grams per typical day, abstinence
days previous to admission, favorite drink (fortified bev-
erages and liquors, wine and beer), pattern of consumption
(daily versus weekend or episodic), morning drinking, pres-
ence of previous treatments for alcohol dependence,
maximum previous abstinence duration.
With respect to severity of alcoholism, we also measured
concentrations of serum gamma glutamyl transferase (GGT),
alanine amino transferase (ALT), aspartate amino transferase
(AST) and mean red cell volume (MCV), higher values on
these blood measures representing higher severity (Deguti
and Gonçalves, 2000). The values were normalized by the
ratio between the value and the laboratory cut-off, so that
relevant increased clinical values were represented by values
greater than 1.
The Alcohol-Related Problems Questionnaire (ARPQ) was
applied to the measurement of eleven binary variables on
admission to treatment as well as the sum score of all
problems (Patience et al., 1997).
The seven diagnostic criteria for alcohol dependence
(DSM-IV) measured on admission to treatment were also
considered binary variables for prognostic factor analysis as
well as the sum between 3 and 7 scores, 3 being the
minimum number of criteria observed for a person to be
assumed as dependent (APA, 1994, 2002).
Prognostic factors measured during treatment
During the 6-month treatment period, prescription of DIS
and ACA and their days of intake were documented. The
daily dose of DIS was 125/250 mg and ACA 1332/1998 mg.
Doctors choosing between DIS and ACA did not follow any
patient severity criteria.
The adherence to consultations was measured. Phases of
consultation (1–4) were measured as an average within
patient, computed as the sum of the phases in all consultations
divided by the number of consultations made by the patient.
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Other factors measured during the treatment period were AA
participation (at least one session) and the prescription of anti-
depressants as well as their days of intake. The antidepressants
prescribed were sertraline, venlafaxine and mirtazapine.
Outcome variables
(a) Time to heavy relapse was defined as the number of
days from treatment start until the first consumption
of five or more standard drinks in one occasion
(Greenfield et al., 1998; Rubio et al., 2001; Guardia
et al., 2002; Johnson et al., 2003; De Sousa and De
Sousa, 2004, 2005; Kiefer et al., 2005; Laaksonen
et al., 2007). A standard drink was that containing
10 g of alcohol, which in Portugal is a glass of beer,
a glass of wine or a measure of distilled alcohol bev-
erage (Babor et al., 2001). Lost to follow-up was
analyzed as censored time.
(b) Absence of heavy relapse during the 6 months was
defined as ‘yes/no’; for lost-to-follow-up cases, the
worst-case scenario was used (Barrias et al., 1997;
Besson et al., 1998; De Sousa and De Sousa, 2004;
Bottlender and Soyka, 2005a).
(c) Abstinence from all alcohol consumption during the
6 months was defined as yes/no; for lost-to-follow-
up cases, the worst-case scenario was used (Barrias
et al., 1997; Besson et al., 1998; Mann et al., 2004;
Bottlender and Soyka, 2005a,b; Verheul et al., 2005;
Feeney et al., 2006; Walter et al., 2006).
(d) Cumulative abstinence duration (CAD) was the sum
of all abstinent days during the 6 months (Barrias
et al., 1997; Besson et al., 1998; Feeney et al.,
2006; Laaksonen et al., 2007); for statistical analysis
dichotomized in two categories: equal/above or
below the sample observed mean of 131 days CAD.
(e) Longest relapse duration (days) was dichotomized in
the categories longest relapse above 1 day versus 0
or 1 day longest relapse.
(f ) Having accumulated at least one problem in ARPQ
during the treatment period was documented at
month 6 as a binary outcome variable (Kiritzé-
Topor et al., 2004).
All the outcome variables representing alcohol consumption
and relapse were recorded in a self-reported Timeline
Followback (TLFB) (Sobell and Sobell, 1992), one of the
more accurate methods for estimation of alcohol consumption
(Del Boca and Darkes, 2003). Two research assistants blind
to the treatment method applied the TLFB using telephone
interviews to patients and their co-responsibles at 15-day
intervals. For cases where patients and co-responsibles dif-
fered, interviewers assumed the most pessimistic version and
a final validation made by researchers, through comparisons
between TLFB and the clinical process of the patient, assum-
ing again the most pessimistic version.
Statistical analysis
Data were analyzed using the Statistical Package for Social
Sciences (SPSS V18). The significance level was assumed at
5% in bilateral hypothesis tests and 95% confidence intervals
(CIs) were also used.
Area under the ROC curve (receiver operating characteris-
tic) was computed to analyze the relationship between
numerical prognostic factors and binary outcomes (Hosmer
and Lemeshow, 1998).
Kaplan–Meier survival analysis was used to analyze the
relationship between prognostic factors and time to first
heavy relapse (Pocock, 1983).
Multiple Cox regression was used to compute the adjusted
hazard ratios (HRs) between each simultaneous prognostic
factors and time to first heavy relapse (Kleinbaum and Klein,
2005; Rothman et al., 2008).
Multiple logistic regression was used to compute adjusted
odds ratios (OR) between each simultaneous prognostic
factors and a binary outcome (Hosmer and Lemeshow, 1998;
Rothman et al., 2008).
From all independent prognostic factors considered, we
selected a restricted set for multivariable analysis. These
variables were selected according to the following criteria:
P < 0.10 in bivariable analysis for at least one outcome vari-
able and non-evidence of co-linearity. Backward selection
controlled by researcher in each step was used to optimize
the regression modelling.
Sensitivity and specificity analysis was done between
several prognostic factors and the mentioned binary outcomes.
RESULTS
Patients’ characteristics at baseline
In the sample of 209 was 84% male, of median age 41 (min–
max: 21–62), median education 6 years (min–max: 2–17),
with 61% in the lowest socio-economic levels (Graffard’s IV
and V).
The median alcohol consumption in a typical day was
192 g (min–max: 35–1080), with a 13 year median duration
of heavy alcohol consumption (min–max: 1–39). About 15,
11, 11 and 10% of the patients reported past use, respective-
ly, of cannabis, benzodiazepines, heroin and cocaine; 69% of
the patients were current smokers or ex-smokers; 51% of the
patients had previous treatments for alcohol dependence and
18% had had previous inpatient treatment.
About 54, 38, 41 and 30% of the patients had increased
values for GGT, AST, ALT and MCV.
The median number of problems from ARPQ was 5 (min–
max: 0–11); the median number of criteria for alcohol
dependence from DSM-IV was 7 (min–max: 3–7).
Possible prognostic factors arising during treatment
About 82% of patients had DIS prescribed [median intake
179 days (min–max: 7–180); 72% had taken it for 120 days
or more]. Only 14% of patients had ACA prescribed: 28%
took it during 120 days or more with a median intake of 90
days (min–max: 20–180). About 10% of the patients had
prescriptions for DIS and ACA simultaneously; 87% of
patients had prescription for at least one of these two
medications.
The median number of visits made by the patient was 4
(min–max: 1–7). The median number of consultation phases
within visits was 1.8 (min–max: 1–4); 40% had 2.5 phases or
more at visits. AAwas attended (at least one meeting) by 18%.
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About 33% of the patients had anti-depressants prescribed
[median intake of 180 days (min–max: 15–180)].
Prognostic factors analysis
The Kaplan–Meier heavy relapse rate was 23% CI (95%) =
(16–29%); relapse rate for any alcohol quantity was 54% CI
(95%) = (47–60%). The mean of the CAD was 131 days CI
(95%) = (122–140).
Table 1, bivariable analysis, shows only the independent
variables included in multivariable analysis that achieved
statistical significance or at least reached P < 0.10 after multi-
variable optimization. The final results of the multivariable
analysis after statistical optimization, as well as adjusted
effect measures are shown in Table 2 and show that on
admission to treatment female gender predicted worse
outcomes; lower socio-economic status predicted worse
outcomes; a full-time job predicted better outcomes, past use
of cocaine predicted worse outcomes; >20 years of excessive
alcohol consumption predicted worse outcomes; patients
with a shorter period of abstinence before treatment, say up
to 7 days, were likely to have better outcomes; a greater
severity of dependence as indicated by morning or before
lunch consumption predicted better outcomes; liver severity
indicated by GGT predicted worse outcomes; patients with
five or more alcohol-related problems on ARPQ at admission
showed worse outcomes.
Multiple regression techniques showed that taking DIS for
120 days at least predicted better outcomes; taking DIS for
less than 120 days predicted worse outcomes regarding all
the six outcome variables; ACA prescription predicted worse
outcomes; attending four or more visits predicted better out-
comes; having a mean of 2.5 or more phases in a consult-
ation predicted better outcomes.
The most important predictors from the treatment itself of
favourable outcomes were the number of days of taking DIS,
adherence to consultations and phases of each consultation.
Regarding heavy relapse, we found areas under ROC curve
of 0.93 (P < 0.001), 0.82 (P < 0.001) and 0.68 (P < 0.001),
respectively for days DIS taken for patients with a DIS pre-
scription, number of consultations made and average of con-
sultation phases. Considering a cut-off of 120 days of taking
DIS, we found that 120 or more days of DIS had a sensitiv-
ity and a specificity of 97 and 68%, respectively, for avoid-
ing heavy relapse in patients with a DIS prescription.
Attending >50% of the seven consultations offered (i.e. four
or more consultations) had a sensitivity and a specificity,
respectively, of 92 and 63% for avoiding heavy relapse. At
least a 2.5 average consultation phases allows a sensitivity
and a specificity of 56 and 77%, respectively for avoiding
heavy relapse.
A patient with a DIS prescription who took DIS for at
least 120 days and attended >50% of the total consultations
(four consultations), the sensitivity and the specificity for
abstinence of heavy drinking are 100 and 61%, respectively
(n = 121 analyzed patients that made DIS ≥120 and consulta-
tions ≥4 versus DIS <120 and consultations <4 simultan-
eously). If we add at least 2.5 phases of consultation to this
analysis (n = 77 patients that made DIS ≥120 and consulta-
tions ≥4 and phases ≥2.5 versus DIS <120 and consultations
<4 and phases <2.5 simultaneously), we get the same sensi-
tivity of 100% and improve the specificity to 71%.
Other association results found
Women in comparison with men had more antidepressant
prescriptions (58 versus 28%; P = 0.001) and a higher rate of
antidepressant use (i.e. for 120 days or more) (30 versus
15%; P < 0.01). For patients with alcohol consumption for
20 years, the number of years of heavy consumption was
positively correlated with CAD (Spearman’s Rs = 0.30; P <
0.01), as well as negatively correlated with the maximum
days of relapse (Spearman’s Rs = –0.19; P < 0.05). Patients
with raised GGT levels had a more prominent pattern of
daily consumption in comparison with patients with normal
GGT (96 versus 89%; P < 0.05), and patients who drank in
the morning and before lunch had higher GGT (median of
1.3 versus 0.89; P < 0.05) levels. Patients with raised GGT
levels were more likely to report all the seven alcohol de-
pendence criteria from DSM-IV (61 versus 44%; P < 0.05).
For patients with a DIS prescription, the number of days
of DIS intake was positively correlated with the number of
visits made by the patient (Spearman’s Rs = 0.47; P < 0.01).
Patients who had DIS or ACA prescription had at baseline a
higher alcohol median quantity on a typical day (192 versus
155 g; P < 0.05).
DISCUSSION
This research identifies prognostic factors in a short-period
follow-up; this is in line with others who advocate the
importance of short-term prognosis (Glenn and Parsons,
1991; McKay and Weiss, 2001; Room et al., 2005).
In this study, relapse to heavy drinking (Kaplan–Meier cu-
mulative incidence) showed a very favourable rate of 23% at 6
months. Even according to the worst-case scenario, the rate of
relapse to any alcohol was 54%, but this is lower than the
61% median relapse rate reported in several studies of alcohol
treatment (Ellis and McClure, 1992; Barrias et al., 1997;
Besson et al., 1998; Chick et al., 2000; Curran et al., 2000;
Rubio et al., 2001; Neto et al., 2007; Nielsen et al., 2007;
Terra et al., 2008). Two possible explanations are the relative-
ly good social support of our patients (70% had a stable rela-
tionship and 92% were not living alone) and the power of the
treatments employed.
That the female gender was associated with worse progno-
sis in this study is consistent with many other studies (Ellis
and McClure, 1992; Walton et al., 2003; Bottlender and
Soyka, 2005a,b; Neto et al., 2007). Some authors attribute
this to higher prevalence of comorbid depression and anxiety
(Rounsaville et al., 1987; Waisberg, 1990; Ellis and
McClure, 1992; Callaghan and Cunningham, 2002; Kusnher
et al., 2005) in females. We found that women compared
with men had a higher rate of prescription and days of anti-
depressants taken, and a (non-significant) higher rate of de-
pression attributed to alcohol in the ARPQ. However, when
we introduced into a multiple regression model the variable
‘days of antidepressant intake’, female gender was still asso-
ciated with a worse prognosis. This result suggests for this
study population that being women could be a factor of poor
prognosis independent of depression, at least in Portugal.
Lower socio-economic levels and more precarious profes-
sional situation emerged as poor prognostic factors (c.f.
Waisberg, 1990; Ellis and McClure, 1992; McKay and
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Table 1 . Bivariable analysis of the prognostic factors included in multivariable analysis—6-month follow-up (maximum n = 209)














above the mean of





Rate of having at
least one problem
in ARPQ at 6
months (n = 192)
Sex (n = 209) Male (176) 78.1% 55.7% 48.9% 67.0% 24.1% 40.4%
Female(33) 72.2% 36.4%* 33.3% 51.5%++ 36.8% 58.1%++
Graffard’s socio-economic level (n = 209) Upper and middle level I, II, III (81) 77.4% 61.7% 53.1% 72.8% 21.5% 33.8%
Lower level IV, V (128) 77.3% 46.9%* 42.2% 59.4%* 28.6% 49.2%*
Professional situation (n = 209) Without full-time job (109) 74.7% 45.0% 41.3% 60.6% 29.3% 50.5%
With full-time job (100) 79.6% 61.0%* 52.0% 69.0% 22.2% 35.2%*
Past use of cocaine (n = 209) Without use (188) 77.9% 55.3% 50.0% 67.0% 26.0% 40.9%
With use (21) 70.5% 28.6%* 14.3%** 42.9%* 20.0% 61.9%++
Years of heavy alcohol consumption (n = 209) ≤10 years (95) 76.6% 46.3% 40.0% 56.8% 26.6% 47.7%
11–20 years (83) 77.8% 65.1% 60.2% 79.5% 19.7% 32.1%
>20 years (31) 79.3% 38.7%* 29.0%** 48.4%*** 42.9%++ 60.7%*
ROC = 0.57++ ROC = 0.56 ROC = 0.57 ROC = 0.52 ROC = 0.56
Abstinence days before treatment (n = 209) >7 days (137) 72.9% 46.7% 42.3% 61.3% 26.3% 48.8%
1–7 days (72) 85.1% 63.9%* 54.2% 70.8% 24.6% 33.3% *
ROC = 0.58++ ROC = 0.55 ROC = 0.53 ROC = 0.51 ROC = 0.61*
Morning or before lunch drinking (n = 209) Does not drink (53) 84.0% 47.2% 35.8% 60.4% 23.5% 46.9%
Drinks (156) 75.3% 54.5% 50.0%++ 66.0% 26.2% 42.0%
GGT (n = 193) Normal (≤1) (88) 81.8% 52.3% 47.7% 63.6% 27.5% 42.0%
Increased (>1) (105) 72.9%++ 57.1% 49.5% 70.5% 24.4% 39.2%
ROC = 0.54 ROC = 0.52 ROC = 0.55 ROC = 0.51 ROC = 0.53
ARPQ sum (0–11) (n = 192) Lower than five problems (70) 88.3% 68.6% 62.9% 82.9% 10.7% 28.6%
Five or more problems (122) 74.5%* 45.9%** 38.5%*** 54.9%*** 30.2%** 51.6%**
ROC = 0.58++ ROC = 0.59* ROC = 0.61* ROC = 0.60++ ROC = 0.57++
Days of DIS intake (n = 186) 0 days (38) 87.9% 44.7% 44.7% 55.3% 17.4% 57.9%
<120 days (42) 45.7% 7.1% 7.1% 21.4% 60.9% 83.8%
≥120 days (106) 87.6%*** 83.0%*** 71.7%*** 97.2%*** 17.6%*** 11.5%***
ROC = 0.93*** (s) ROC = 0.89*** (s) ROC = 0.97*** (s) ROC = 0.82*** (s) ROC = 0.92*** (s)
The presence of ACA prescription (n = 209) Not done ACA (179) 80.4% 52.5% 46.9% 63.7% 21.7% 44.2%
Did ACA (30) 61.2%* 53.3% 43.3% 70.0% 44.4%* 37.9%
Adherence to doctors consultations (1–7)
(n = 209)
1–3 (71) 67.4% 12.7% 12.7% 16.9% 42.9% 86.4%
4–7 (138) 81.5%*** 73.2%*** 63.8%*** 89.1%*** 21.9%* 20.6%***
ROC = 0.82*** ROC = 0.75*** ROC = 0.90*** ROC = 0.59++ ROC = 0.86***
Average of consultation phases (1–4) (n = 209) <2.5 Phases(125) 68.3% 39.2% 35.2% 54.4% 38.4% 54.4%
≥2.5 Phases (84) 89.3%*** 72.6%*** 63.1%*** 79.8%*** 10.0%*** 26.9%***
ROC = 0.68*** ROC = 0.65*** ROC = 0.64*** ROC = 0.69*** ROC = 0.66***
*P < 0.05 on Log-rank test for survival curves comparison or chi-square/Fisher exact test for group comparison or test of area under the ROC = 0.50.
**P < 0.01.
***P < 0.001.
++P < 0.10, (.), maximum number of cases within a category of a prognostic factor; ROC, area under the ROC curve (always area >0.50 according to code 1 or 0 of the binary outcome); %, outcome rate within
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Table 2. Prognostic factor results from multivariable regression analysis (Cox and Logistic) at a 6-month follow-up
Prognostic factor Variable categories
Time to heavy
relapse (five or
more drinks in a
day) (n = 176)
Abstinence of heavy
drink (days with less
than five alcohol







above the mean of





Having at least one
problem in ARPQ at
6 months (n = 171)
HR OR OR OR OR OR
Sex Male REF — — — — 1 —
Female 4.551*
Graffard’s socio-economic level Upper and middle level (I, II, III) REF — 1 1 1 — —
Lower level (IV, V) 0.324* 0.414* 0.054**
Professional situation Without full-time job REF — — — — — 1
With full-time job 0.368*
Past use of cocaine Without use REF — 1 1 1 — —
With use 0.110** 0.051*** 0.112++
Years of heavy alcohol consumption ≤10 years REF — — 1 1 1 1
11–20 years 1.288 2.880 1.544 1.243
>20 years 0.199* 0.051* 8.360** 7.319**
Abstinence days prior to treatment >7 days REF 1 1 — — — —
1–7 days 0.387* 2.662++
Morning or before lunch drinking Does not drink REF — — 1 — — —
Drinks 3.012*
GGT Normal (≤1) REF 1 — — — — —
Increased (>1) 2.295*
ARPQ sum (0–11) Lower than five problems REF — — — 1 1 —
Five or more problems 0.036** 2.577++
Days of DIS intake 0 days REF 1 1 1 1 1 1
<120 days 12.613*** 0.062*** 0.050*** 0.084* 15.600** 5.246*
≥120 days 2.893 1.793 0.820 18.877** 3.133 0.163***
Presence of ACA prescription Not done ACA REF 1 — — — 1 —
Did ACA 2.806* 2.742++
Adherence to doctors consultations (1–7) 1–3 REF — 1 1 1 — 1
4–7 9.097*** 5.556*** 177.5*** 0.074***
Average of consultation phases (1–4) <2,5 Phases REF 1 1 1 — 1 —
≥2,5 Phases 0.268** 2.800* 3.242* 0.207**
Model P value — P<0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001
Hosmer–Lemeshow P-value P = 0.77 P = 0.52 P = 0.71 P = 0.50 P = 0.11
Model area under ROC curve and P-value 90%, P < 0.001 88%, P < 0.001 98%, P < 0.001 82%, P < 0.001 91%, P < 0.001
HR, hazard ratio adjusted for co-variables by multiple Cox regression; OR, odds ratio adjusted for co-variables by multiple logistic regression; REF, reference category for comparison.
*P < 0.05 Wald test.
**P < 0.01 Wald test.
***P < 0.001 Wald test.
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Weiss, 2001; Walton et al., 2003; Bottlender and Soyka,
2005a,b; Moos and Moos, 2006; Ilgen et al., 2007).
Previous cocaine predicted worse prognosis (c.f.
Rounsaville et al., 1987; Callaghan and Cunningham, 2002).
Considering severity of alcohol consumption, it was found
that heavy consumption over 20 years, having a raised serum
GGT level and having at least 5 of the 11 problems of
ARPQ predicted poor outcomes, use for >20 years being the
most important prognostic factor in number of statistically
significant results, namely in four of the six outcome vari-
ables. A more severe history of alcohol consumption asso-
ciated with a worse prognosis is expected from previous
studies (Rounsaville et al., 1987; McLellan et al., 1994;
McKay and Weiss, 2001; Staines et al., 2003; Bottlender and
Soyka, 2005a; Moos and Moos, 2006; Ilgen et al., 2007). An
important aspect of the duration of alcohol consumption in
this study is that prognosis improves with duration of use up
to 20 years, after which this trend is reversed. It was found
with statistical significance for patients with alcohol con-
sumption for up to 20 years that the number of years of con-
sumption was positively correlated with CAD as well as
negatively correlated with the maximum duration of relapses.
This suggests that as duration of alcohol consumption
increases until a certain cut-off, say 20 years, it also increases
the likelihood of better prognosis naturally associated with
an increased age of the patients.
Raised serum GGT level at baseline was important, par-
ticularly as a predictor of time to the first heavy relapse.
Higher GGT level was associated with a pattern of daily con-
sumption, as well as drinking in the morning, which in turn
are two important indicators of the severity of consumption
(Stockwell et al., 1983; Ellis and McClure, 1992; Babor
et al., 2001; Ilgen et al., 2007). Also, GGT level was asso-
ciated with meeting the seven DSM-IV criteria for diagnosis
of alcoholism, another possible indicator of severity
(Schuckit et al., 1997). Thus, it appears that GGT level is an
important prognostic factor reflecting severity and should be
taken into account in alcohol studies.
Less expected was the fact that patients with morning or
before-lunch alcohol consumption had better prognosis, since
drinking in the morning or before lunch is an indicator of se-
verity of consumption (Stockwell et al., 1983; Babor et al.,
2001). One possible explanation for this is that patients with
more severity in some indicators may also have greater motiv-
ation to recover from their alcohol problems and consequently
adhere better to treatment. In this sense, some authors suggest
that higher levels of severity of patients at admission to treat-
ment can be associated with better prognosis after treatment
(Waisberg, 1990; McKay and Weiss, 2001).
An important result was that patients who entered treatment
with a shorter period of abstinence, say up to a week, had a
better prognosis than patients with more abstinent days before
treatment. Motivation of patients to initiate a formal and
longer treatment may be highest during or soon after detoxifi-
cation. Chick et al. (2000) offered as one explanation for the
ineffectiveness of drug treatment in their study the fact that
there had been a long time, even several weeks, between de-
toxification and the start of drug treatment for many patients.
The advantage of taking DIS for at least 120 days is con-
sistent with other reports of supervised DIS (Chick et al.,
1992; Mello et al., 2001; Niederhofer and Staffen, 2003; De
Sousa and De Sousa, 2004; Laaksonen et al., 2007; Neto
et al., 2007). We found that the number of days of DIS
intake for patients who took it at least for one day revealed a
high capacity for discriminating good prognosis, areas under
the ROC curve for good prognostic being significant for all
outcome variables and varying between 82 and 97% (93%
for abstinence of heavy drinking). The 120-day cut-off point
for patients who took DIS showed a high sensitivity and a
relatively sufficient specificity of 97 and 68%, respectively,
for avoiding a heavy drinking day (The cut-off of 120 days
was based on work by Neto et al. (2007), which demon-
strated the better effectiveness of DIS with at least 120 days
of intake).
Taking DIS for less than 120 days proved to be one of the
worst prognostic factors in this study, being associated with
worse prognosis in all the outcome variables considered and
having high risk ratios in multivariable analysis. We can
speculate that cessation of DIS and consequent lack of effect-
iveness may relate to lack of adequate supervision and mo-
tivation of the co-responsible (Chick et al., 1992; Hughes
and Cook, 1997; Room et al., 2005; Laaksonen et al., 2007).
In respect of ACA, we found lack of effectiveness, as was
already observed, for example, by Chick et al. (2000) and
studies that found DIS superior to ACA (De Sousa and De
Sousa, 2005; Laaksonen et al., 2007). Unlike DIS, the
number of days of ACA intake was not statistically asso-
ciated with good prognosis, showing areas under the ROC
curve of low magnitude and not statistically significant for
patients with at least one day of intake. This suggests that
greater number of days of ACA intake is not associated with
better prognosis. One issue important to notice is that the
median time of ACA intake was 90 days, about half of the
time of DIS intake (179 days). This lack of motivation to
persist with ACA medication could be one of the reasons
why the ACA patients had worse prognosis. It is important
to note that the preference between DIS and ACA was not
dependent on patient severity: there were no significant dif-
ferences between DIS patients and ACA patients (exclusive
treatment groups) in respect of severity, including the
number of years of heavy drinking, alcohol quantity in a
typical day, median number of DSM-IV criteria and GGT
level (results not shown). However, this was not a random
double-blind comparative trial of DIS versus ACA and there-
fore, there might be unknown confounders—indeed perhaps
more motivated patients will request DIS.
The number of visits made by the patient was important,
the multivariable analysis showing relevant associations in
four of the six outcome variables and areas under ROC
curves showing significance related to visits attended.
Indeed, attending more than half of the planned visits had a
sensitivity of 92% and a specificity of 63% for absence of
heavy drinking. (c.f. McKay and Weiss, 2001; McCrady and
Epstein, 2004; Mann et al., 2005; Terra et al., 2008).
Attending visits reinforces DIS adherence: the number of
days of DIS taken correlated positively with the number of
visits attended. The number of visits attended plus the
number of days that DIS was taken improves sensitivity from
97% for DIS (at least 120 days taken) and 92% from visits
attended (>50% of visits) to a sensitivity of 100% regarding
absence of heavy drinking for patients with DIS prescription.
This means that 100% of patients who avoided heavy relapse
took DIS for >120 days and attended >50% of the planned
visits (assuming that these patients had DIS prescription).
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The greater number of phases in the consultation was also
prognostic of good outcomes for four of the six outcome
variables. (c.f. Neto et al., 1997; David et al., 1998; Neto
et al., 2008). We think that this is due to greater involvement
of the co-responsible.
If we add the consultation type (more than two phases) to
a patient who was already taking DIS for at least 120 days
and >50% of the planned consultations, then we maintain
the sensitivity of absence from heavy drinking at 100% but
increase the specificity for 71% (assuming that these patients
had DIS prescription). This means that 71% of heavy
relapsed patients made fewer DIS (<120 days), with fewer
visits (<4) and with fewer consultation phases (<2.5).
Regarding AA, this study did not support the association
with good prognosis found by many others (e.g. Ellis and
McClure, 1992; McKay and Weiss, 2001; Mello et al., 2001;
McCrady and Epstein, 2004; Room et al., 2005; Ilgen et al.,
2007; Chong and Lopez, 2008; Terra et al., 2008). However
the low rate of AA attendance (18%) in our study does not
lead to any conclusions.
Our sample comprised severely affected patients, similar
to many alcohol-dependent patients in treatment. Our sample
comprised 84% of males, with 41 years of median age, con-
suming a median of 192 g of alcohol during a median of 13
years of heavy drinking. If we consider the similar median
values of several studies of alcohol-dependent persons in
treatment, we get 74% of male patients with 43 years of
median age, consuming a median of 193 g of alcohol during
a median of 14 years of heavy drink (Ellis and McClure,
1992; McLellan et al., 1994; Barrias et al., 1997; Besson
et al., 1998; Chick et al., 2000; Curran et al., 2000; Rubio
et al., 2001; Guardia et al., 2002; Willinger et al., 2002;
Johnson et al., 2003; Staines et al., 2003; Kiritzé-Topor
et al., 2004; De Sousa and De Sousa, 2004; Bottlender and
Soyka, 2005a; Kiefer et al., 2005; Kushner et al., 2005;
Mann et al., 2005; Feeney et al., 2006; Gordon et al., 2006;
Neves-Cardoso et al., 2006; Sander and Jux, 2006; Walter
et al., 2006; Laaksonen et al., 2007; Neto et al., 2007;
Nielsen et al., 2007; Terra et al., 2008). Thus, we believe our
findings can be extrapolated to other patient populations.
Several limitations pertain. We had 28% lost to follow-up
(who were classified as relapsed and for missing values of
ARPQ at 6 months—about 36%—, classified as having at
least one alcohol problem). Regarding external validity and
generalization of results, one of the conditions for inclusion
was the availability of a close person to inform or be
co-responsible; this does not apply across the whole spec-
trum of alcohol-dependent patients.
Nevertheless, we believe that this study sheds light on
some important features of treatment in a real environment.
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